RANDALL J. GALL, MD

Plain English
This study examined how brain connections in stroke patients differ between resting and when performing a visual task, particularly in those with a condition called spatial neglect (SN), which makes it hard to pay attention to one side of their environment. The researchers found that patients with SN had significantly lower connectivity in key brain areas compared to those without neglect, with an accuracy of 87% in identifying neglect during rest and 81% during the task. These findings matter because they can help develop targeted rehabilitation strategies that improve attention and aid recovery for stroke patients. Who this helps: This helps stroke patients dealing with spatial neglect and their healthcare providers.

Plain English
This study focused on improving how we detect where people are paying attention in a noisy environment, like a party, using brain activity measurements (EEG). Researchers developed a new technique that processes EEG data more efficiently, achieving up to a 10% increase in accuracy while using 87.5% fewer EEG channels and requiring 75% less memory compared to older methods. This is important because it allows devices like hearing aids to work better with less power and memory, making them more effective in real-world situations. Who this helps: Patients with hearing difficulties and users of hearing aid devices.

Plain English
This study focused on a new system called AREEN, which uses augmented reality and brain activity tracking (EEG) to detect spatial neglect in stroke patients. Researchers tested different methods to see which one was best for accurately identifying neglect, finding that the boosted tree model was most effective, correctly identifying 90.9% of patients with neglect and 90.0% without it. This improvement matters because accurately diagnosing spatial neglect can lead to better rehabilitation plans for patients. Who this helps: Stroke patients dealing with spatial neglect.

Plain English
This study investigates whether the drug dupilumab can help adults with a specific type of asthma achieve clinical remission. The researchers are looking at 150 participants who have struggled with severe asthma attacks and elevated biomarkers of asthma, splitting them into two groups: one receiving dupilumab and the other a placebo. The results are expected to show if dupilumab can reduce severe asthma attacks and improve overall lung function over 56 weeks. Who this helps: This benefits patients with at-risk type-2 inflammatory asthma.

Plain English
This study looked at how well dupilumab, a medication that targets specific asthma-related inflammation, works in children aged 6 to 11 with moderate to severe asthma and high levels of certain blood cells called eosinophils. The results showed that children taking dupilumab experienced 67% fewer severe asthma attacks compared to those who received a placebo and had better lung function after 24 and 52 weeks. These findings are important because they highlight that dupilumab can significantly improve asthma control in these children with high eosinophil levels without increasing safety risks. Who this helps: Patients with moderate to severe asthma, especially those with elevated eosinophil levels.

Plain English
This research studied the effects of a drug called dupilumab on patients with moderate-to-severe asthma who had high levels of a marker called Feno, which indicates inflammation in the lungs. The findings showed that dupilumab significantly reduced the number of severe asthma attacks by 58% to 59% compared to a dummy treatment (placebo) and improved lung function and quality of life scores for all patients, whether they had a notable early decrease in Feno levels or not. This is important because it shows that dupilumab can provide lasting benefits for asthma patients, helping to control their symptoms and improve their daily lives. Who this helps: This helps patients with type 2 asthma.

Plain English
This study looked at the real-life challenges faced by children with asthma in the US and five European countries. Out of 1,332 young patients, about 80% had asthma symptoms in the past month, with 62% experiencing at least one asthma flare-up in the last year, and many also had other health issues related to asthma. The findings show that most children with asthma have ongoing symptoms and complications, indicating a need for better treatments and care strategies. Who this helps: This helps pediatric patients with asthma and their healthcare providers.

Plain English
This study looked at the use of oral corticosteroids (OCS) in people with severe asthma, which can be helpful but also lead to serious health issues like osteoporosis and diabetes. Despite knowing these risks, many patients still rely on OCS for treatment. It found that using other medications, called biologics, can reduce the need for OCS and improve asthma control, highlighting the importance of finding safer treatment methods. Who this helps: This benefits patients with severe asthma and their healthcare providers.

Plain English
This study looked at how effective and acceptable it is for women to collect their own samples for HPV testing as a way to screen for cervical cancer. Out of 156 women, only 6.4% tested positive for HPV, which shows that self-collection can work well. Most women found the self-collection process easy and convenient, with 70.6% preferring it over traditional doctor-collected samples, meaning it could significantly improve access to screening for cervical cancer. Who this helps: This helps women who may not have easy access to traditional cervical cancer screenings, especially those in underserved communities.

Plain English
This study examined a specific enzyme called BroSCO that helps fungi create a substance known as peptidomelanin, which is important for their growth. The researchers discovered that BroSCO is able to combine a common building block called L-DOPA with other small molecules, resulting in the production of peptidomelanin. This finding reveals a new biochemical pathway in fungi, enhancing our knowledge of how these organisms work and potentially influencing future research and applications. Who this helps: This benefits researchers studying fungi and their biochemistry.

Plain English
This study looked at how using oral corticosteroids (OCS) affects patients with severe asthma before they start biologic treatments. It included data from over 4,300 patients across 23 countries, finding that 40.9% were on long-term OCS, which can lead to a misleading assessment of their asthma based on blood eosinophil counts (BEC). For example, among those on long-term OCS, 28.6% had a BEC below 150 cells/µL, indicating a potential misclassification of their asthma severity. Who this helps: This helps patients with severe asthma and their doctors in understanding treatment options and managing their condition better.

Plain English
This study looked at how well a medication called dupilumab works for people aged 12 and older with moderate-to-severe asthma. After two years of treatment, patients showed significant improvements in their lung function, with increases of about 0.52 liters after 48 weeks and 0.45 liters after 96 weeks of taking dupilumab. The findings are important because they show that dupilumab can provide long-lasting benefits for asthma patients, even for those who had not taken the medication before. Who this helps: This helps asthma patients who struggle with their lung function, especially those with elevated type 2 markers.

Plain English
This study looked at how lung function affects the rate of asthma flare-ups in children aged 6 to 11 who were treated with a medication called dupilumab for moderate-to-severe asthma. The results showed that 60% of the children taking dupilumab improved their lung function after 12 weeks, compared to 50% who took a placebo, and overall, dupilumab reduced severe asthma flare-ups by 52-60% compared to placebo over the course of the treatment. This is important because better lung function can lead to fewer asthma attacks, improving the quality of life for children with asthma. Who this helps: This helps children with asthma and their families.

Plain English
This study looked at how effective the medication dupilumab is for children aged 6 to 11 with severe asthma that doesn't respond well to other treatments. Researchers found that dupilumab significantly lowered the risk of severe asthma attacks by 53% to 96% compared to a placebo and improved lung function and asthma control scores after one year of treatment. This is important because it shows that dupilumab can benefit children with different levels of previous asthma attacks, helping them breathe easier and manage their condition better. Who this helps: This helps children with uncontrolled moderate-to-severe asthma and their doctors.

Plain English
This study looked at how a medication called dupilumab affects asthma symptoms in patients with moderate-to-severe asthma, specifically focusing on changes in two biomarkers: fractional exhaled nitric oxide (FeNO) and blood eosinophil count (Eos). Researchers found that while dupilumab reduced asthma flare-ups, the changes in these biomarkers didn’t correlate with the number of flare-ups experienced. For the dupilumab group, FeNO levels dropped significantly, which was linked to better lung function, but this prediction didn’t apply to the overall reduction in flare-ups. Who this helps: This research benefits asthma patients and their doctors by providing insights and potential treatment options.

Plain English
This study looked at asthma in children, focusing on a specific type of inflammation called type 2 inflammation, which is present in most cases of pediatric asthma. Researchers found that many children respond well to standard treatments, but a significant number—about 10-20%—still struggle to manage their symptoms, putting them at risk for serious asthma attacks. Understanding this type of inflammation is crucial because it helps in identifying and treating various triggers of asthma in kids. Who this helps: This information benefits children with asthma and their doctors, especially in managing severe cases.

Plain English
This study looked at the effects of dupilumab, a medication for asthma, in children aged 6 to 11 with moderate-to-severe asthma over two years. The results showed that children taking dupilumab had a lower rate of severe asthma attacks and better lung function compared to those who had received a placebo and then switched to dupilumab. Specifically, the children on dupilumab experienced significant improvements, leading to fewer exacerbations and better breathing capacities over the study period. Who this helps: This benefits children with moderate-to-severe asthma and their doctors by providing an effective treatment option.

Plain English
This study looked at a method called AttentionCARE, which uses augmented reality and brain activity feedback to help teenagers, especially those at high risk for depression, focus better on important tasks instead of getting sidetracked by negative emotions. The researchers found that their approach reliably helped ten adolescents improve their attention by reducing the impact of negative emotional distractions. This is important because it suggests a new way to potentially prevent depression in young people by improving their ability to focus. Who this helps: This helps adolescents at high risk for depression, particularly those with a family history of the condition.

Plain English
This study looked at a new form of melanin called peptidomelanin, which is produced by certain fungal spores. Researchers found that this water-soluble melanin can trap heavy metals like lead, mercury, and uranium, making it potentially useful for cleaning up contaminated environments. Specifically, it has been shown to effectively remove large amounts of these harmful metals, which could be beneficial in farming and other areas affected by heavy metal pollution. Who this helps: This research benefits environmental cleanup efforts and agricultural practices.

Plain English
This study focused on measuring the severity of spatial neglect in stroke patients by using EEG technology. The researchers developed a new system called ESTNet, which accurately assesses how much of a person's field of view is affected by neglect, achieving an accuracy of about 79.62%. This improvement in assessment methods can help create better treatment plans for those suffering from this condition. Who this helps: This helps stroke patients with spatial neglect and their healthcare providers.

Plain English
This study looked at how a medication called dupilumab affects lung function in patients with moderate-to-severe asthma who have certain elevated markers in their blood. Researchers found that after taking dupilumab, patients improved their lung function by an average of 0.17 liters compared to those taking a placebo, and this improvement lasted for at least a year. This is important because better lung function can lead to fewer asthma attacks and better control of asthma symptoms. Who this helps: Patients with moderate-to-severe type 2 asthma.

Plain English
This study looked at how well a drug called dupilumab works for people in Latin America who have severe asthma that isn't well controlled. The researchers found that patients taking dupilumab experienced 52.7% fewer severe asthma attacks compared to those on a placebo, and their lung function improved by 0.15 liters after 12 weeks of treatment. This is important because it shows that dupilumab can significantly help Latin American patients with this specific type of asthma. Who this helps: This helps patients in Latin America suffering from uncontrolled moderate-to-severe asthma.

Plain English
This study looked at how doctors across the U.S. manage kids with moderate-to-severe asthma and identified some educational gaps in their practices. Findings showed that while most doctors try to follow guidelines, there is no single set of guidelines they prefer, and many struggle to assess how severe a child's asthma is or how to involve parents and kids in treatment decisions. Specifically, 55% of general pediatricians had difficulty distinguishing between control and severity of asthma, and there was little agreement on managing patients with ongoing symptoms even after treatment. Who this helps: This benefits pediatricians and the patients they treat, leading to better asthma management for children.

Plain English
This study looked at how effective the drug dupilumab is for people with severe asthma, whether or not it is triggered by allergies. Researchers found that dupilumab significantly reduced severe asthma attacks by 60% to 72% compared to a placebo and improved lung function and quality of life in patients. It also helped decrease the need for oral corticosteroids, which are often used to control asthma flare-ups. Who this helps: This research benefits asthma patients, particularly those struggling to control their symptoms with traditional medications.

Plain English
This study looked at patients with asthma who started treatment with a drug called dupilumab in everyday medical settings, rather than in controlled clinical trials. Researchers are gathering information from around 1,000 patients to see how well the drug works over three years and to monitor any side effects. The findings will help improve the understanding of how dupilumab helps patients manage their asthma and enhances their quality of life. Who this helps: This helps patients with moderate-to-severe asthma who may benefit from dupilumab treatment.

Plain English
This study looked at how the drug dupilumab affects children aged 6 to 11 with moderate-to-severe asthma, focusing on how it changes certain markers linked to asthma inflammation. The results showed that dupilumab significantly reduced severe asthma flare-ups and improved lung function, with markers like total immunoglobulin E dropping by about 78.6% after 52 weeks of treatment. This is important because it shows that dupilumab can effectively manage asthma symptoms and inflammation in children, potentially leading to better overall health and quality of life. Who this helps: This helps children with moderate-to-severe asthma and their caregivers.

Plain English
This study looked at how an asthma medication called dupilumab works in children aged 6 to 11 who have moderate-to-severe type 2 asthma, whether or not they show signs of allergic asthma. Researchers found that dupilumab reduced the number of severe asthma attacks by 62% in children with allergic asthma and by 51% in those without allergic asthma. The treatment also improved lung function and asthma control scores in children with allergic asthma, but less improvement was seen in those without. Who this helps: This benefits children with asthma, especially those with allergic asthma.

Plain English
This study looked at how well a treatment called dupilumab works for people with moderate-to-severe asthma that doesn’t respond well to other treatments, regardless of whether they have allergies. After 96 weeks of treatment, patients experienced fewer severe asthma attacks, and their lung function improved by up to 0.44 liters, indicating better breathing. This matters because it shows that dupilumab can significantly help manage asthma symptoms over the long term. Who this helps: This helps patients with uncontrolled asthma, especially those with type 2 inflammation.

Plain English
This study looked at how well the medication dupilumab works for asthma patients who have trouble sleeping. It found that 64% of patients with type 2 asthma experienced high sleep disturbances, and those whose asthma was more severe were even more affected. After 52 weeks of treatment with dupilumab, patients had less nighttime symptoms, a significant reduction in severe asthma attacks by 66%, and an improvement in lung function. Who this helps: This research benefits asthma patients, particularly those with type 2 asthma and sleep issues.

Plain English
The VOYAGE study examined the effects of a medication called dupilumab on children aged 6 to 11 with moderate to severe asthma that was hard to control. After 52 weeks, 70% of children taking dupilumab had better asthma control, compared to just 46% of those taking a placebo. Moreover, their quality of life and that of their caregivers also improved significantly. Who this helps: This helps children with asthma and their caregivers by improving their daily lives and disease management.

Plain English
This study looked at how feeding problems in newborns, like difficulties in sucking and swallowing, affect their hospital stay. It found that infants with feeding-related events stayed in the hospital twice as long, with average costs of $160,165 compared to $64,380 for those without these issues. This is important because understanding these challenges can help improve care practices and reduce the costs of hospitalization for newborns. Who this helps: This helps doctors and healthcare providers caring for newborns.

Plain English
This research focused on a new method called replica-exchange enveloping distribution sampling (RE-EDS) that can quickly predict how well different small molecules (ligands) will bind to specific proteins (kinases). The team tested this method on 42 different ligands across four kinases and found that it can analyze up to 13 ligands at once, making the process much faster and cheaper than traditional methods, which often require separate calculations for each pair of molecules. This advancement is significant because it streamlines drug design, potentially leading to faster development of new medications. Who this helps: Patients, researchers, and pharmaceutical companies involved in drug development.

Plain English
This study looked at how well the medication dupilumab works for patients with severe asthma who depend on oral corticosteroids (OCS) to manage their symptoms, focusing on different starting doses of OCS. The results showed that after treatment, patients who took dupilumab had significantly fewer asthma attacks, a 0.202 to 0.366 annual rate of exacerbations, and over two-thirds managed to reduce their OCS doses to 5 mg or less by 48 weeks. This matters because it demonstrates that dupilumab can effectively improve lung function, asthma control, and quality of life for these patients, regardless of the severity of their condition. Who this helps: This helps patients with severe asthma who rely on corticosteroids for their treatment.

Plain English
This study looked at how well dupilumab, a drug for severe asthma, can help patients reduce their use of oral corticosteroids (OCS) over a longer period. Patients who continued treatment with dupilumab saw their average OCS use drop significantly, from 11.0 mg daily to just 1.2 mg daily after 96 weeks, a reduction of nearly 90%. This is important because lowering corticosteroid use can reduce side effects, making asthma management safer and more effective. Who this helps: Patients with severe asthma who rely on corticosteroids for control.

Plain English
This study looked at how well a medication called dupilumab works for patients with type 2 asthma who are already using high doses of inhaled steroids. The findings showed that dupilumab significantly lowered the number of severe asthma attacks and improved lung function after 12 weeks, with a 53% reduction in exacerbations, while it also enhanced asthma control scores after 24 weeks. These results are important because they indicate that dupilumab can be beneficial for patients who are not well-controlled on high-dose inhaled corticosteroids. Who this helps: This helps patients with type 2 asthma, particularly those struggling despite high doses of steroid treatment.

Plain English
This study looked at the higher rates of skin cancer, specifically melanomas and keratinocyte cancers, among active-duty US military personnel. Researchers found that these servicemembers face greater risks due to increased sun exposure, lack of protective measures, and not enough education about these risks. This matters because addressing these issues can help reduce skin cancer cases without interfering with military effectiveness. Who this helps: This helps military personnel by promoting better skin cancer prevention and awareness.

Plain English
This study looked at how the bladders of patients with postural tachycardia syndrome (PoTS) work. Researchers reviewed the bladder tests of 50 patients, mostly women, and found that 30% of them needed to use catheters to help them urinate, and 13% experienced involuntary bladder contractions. These findings indicate that many people with PoTS may have bladder problems that require special management, making it important for doctors to understand these issues. Who this helps: This helps patients with PoTS and their healthcare providers.

Plain English
This study looked at two patients who developed infections called nasal septal abscesses after surgery to reshape their noses, where special adhesives and plates were used to support grafts. Both patients had abscesses about 8 weeks later, requiring treatment, and the use of the adhesive called Dermabond was linked to a significantly higher risk of infection, with a 15 times greater chance compared to similar patients who didn’t use it. This matters because it suggests that using Dermabond in this surgical procedure might increase the likelihood of complications, leading surgeons to consider safer alternatives. Who this helps: This helps doctors and surgeons who perform nose surgeries.

Plain English
This study looked at the safety of a sublingual tablet that helps children and teenagers who are allergic to five types of grass pollen. Out of 829 young patients, 27.4% had some reactions to the tablet, with most being mild like throat irritation and mouth swelling. Overall, the treatment was found to be safe and well tolerated, with 84.7% of patients feeling good about it. Who this helps: This research benefits children and adolescents with grass pollen allergies and their families.

Plain English
This study looked at patients who experience eye discomfort but have normal eye alignment when looking at things close up and far away. Researchers tested 80 people, split into 30 with symptoms and 50 without, to see which eye tests could help distinguish between those who had these symptoms and those who did not. They found that 18 of the symptomatic patients had difficulty with certain eye coordination tests (called vergence facility), while the asymptomatic group did not show these issues, which helps doctors identify vision problems more quickly and accurately. Who this helps: This helps patients suffering from binocular vision issues and their eye care professionals.

Plain English
This study looked at how the water content and sugar levels in the bark of Norway spruce trees relate to each other and how they are affected by bark thickness. Researchers found that the water content in the phloem (the tree tissue that transports sugars) varied significantly, showing a strong link to the amount of sugar present, but changes in bark thickness didn’t reflect these water content changes. Understanding these relationships is important because it helps us learn how trees manage water and nutrients, especially in varying climates. Who this helps: This helps researchers and environmental scientists studying tree health and climate impact.

Plain English
This study looked at how well people can adjust their focus when using different lenses and how that relates to visual symptoms in school children and adults. It found that for children, specific tests could clearly separate those who reported vision problems from those who did not, with significant differences noted in both standard and adjusted tests (p = 0.0004 and p = 0.0055, respectively). In adults, while the adjusted test did show a significant difference (p = 0.0228), standard tests did not provide useful insight. This matters because being able to identify vision issues using reliable tests can help improve care and treat symptoms effectively. Who this helps: This helps children and adults experiencing visual symptoms, as well as their eye care professionals.

Plain English
This study looked at how higher levels of carbon dioxide (CO₂) in the environment affect the seeds and seedlings of a plant called Bromus erectus. Researchers found that while seeds from plants grown in high CO₂ had more mass, they didn't germinate or grow into seedlings any better than those from normal CO₂ environments. However, when seedlings were grown in high CO₂, they grew larger, indicating that the seedlings directly benefit more from the increased CO₂ than the seeds produced under those conditions. Who this helps: This research is useful for farmers and environmental scientists who want to understand how climate change impacts plant growth.